United States Hemophilia Drugs Market Report 2017

August 2017 | 121 pages | ID: U56C8878083EN
QYResearch

Abstracts

In this report, the United States Hemophilia Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

• The West
• Southwest
• The Middle Atlantic
• New England
• The South
• The Midwest
• with sales (volume), revenue (value), market share and growth rate of Hemophilia Drugs in these regions, from 2012 to 2022 (forecast).

United States Hemophilia Drugs market competition by top manufacturers/players, with Hemophilia Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

• Baxalta
• Bayer
• CSL Behring
• Novo Nordisk
• Pfizer
• Roche
• Alnylam Pharmaceuticals
• Amarna Therapeutics
• Asklepios BioPharmaceutical
• Biogen
• BioMarin
• Catalyst Bioscience
• Chiesi Farmaceutici
• Dimension Therapeutics
• Emergent BioSolutions
• Grifols, Kedrion Biopharma
• Octapharma
• rEVO Biologics
• OPKO Biologics
• Sangamo Biosciences
• Spark Therapeutics
• Swedish Orphan Biovitrum
• UniQure Biopharma.

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

• Hemophilia A
• Hemophilia B
• Hemophilia C

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Hemophilia Drugs for each application, including

• Clinic
• Hospital

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

United States Hemophilia Drugs Market Report 2017

1 HEMOPHILIA DRUGS OVERVIEW

1.1 Product Overview and Scope of Hemophilia Drugs
1.2 Classification of Hemophilia Drugs by Product Category
  1.2.1 United States Hemophilia Drugs Market Size (Sales Volume) Comparison by Type (2012-2022)
  1.2.2 United States Hemophilia Drugs Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
  1.2.3 Hemophilia A
  1.2.4 Hemophilia B
  1.2.5 Hemophilia C
1.3 United States Hemophilia Drugs Market by Application/End Users
  1.3.1 United States Hemophilia Drugs Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
  1.3.2 Clinic
  1.3.3 Hospital
1.4 United States Hemophilia Drugs Market by Region
  1.4.1 United States Hemophilia Drugs Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 The West Hemophilia Drugs Status and Prospect (2012-2022)
  1.4.3 Southwest Hemophilia Drugs Status and Prospect (2012-2022)
  1.4.4 The Middle Atlantic Hemophilia Drugs Status and Prospect (2012-2022)
  1.4.5 New England Hemophilia Drugs Status and Prospect (2012-2022)
  1.4.6 The South Hemophilia Drugs Status and Prospect (2012-2022)
  1.4.7 The Midwest Hemophilia Drugs Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Hemophilia Drugs (2012-2022)
  1.5.1 United States Hemophilia Drugs Sales and Growth Rate (2012-2022)
  1.5.2 United States Hemophilia Drugs Revenue and Growth Rate (2012-2022)

2 UNITED STATES HEMOPHILIA DRUGS MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Hemophilia Drugs Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Hemophilia Drugs Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Hemophilia Drugs Average Price by Players/Suppliers (2012-2017)
2.4 United States Hemophilia Drugs Market Competitive Situation and Trends
  2.4.1 United States Hemophilia Drugs Market Concentration Rate
  2.4.2 United States Hemophilia Drugs Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Hemophilia Drugs Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES HEMOPHILIA DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)

3.1 United States Hemophilia Drugs Sales and Market Share by Region (2012-2017)
3.2 United States Hemophilia Drugs Revenue and Market Share by Region (2012-2017)
3.3 United States Hemophilia Drugs Price by Region (2012-2017)

4 UNITED STATES HEMOPHILIA DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)

4.1 United States Hemophilia Drugs Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Hemophilia Drugs Revenue and Market Share by Type (2012-2017)
4.3 United States Hemophilia Drugs Price by Type (2012-2017)
4.4 United States Hemophilia Drugs Sales Growth Rate by Type (2012-2017)

5 UNITED STATES HEMOPHILIA DRUGS SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States Hemophilia Drugs Sales and Market Share by Application (2012-2017)
5.2 United States Hemophilia Drugs Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 UNITED STATES HEMOPHILIA DRUGS PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Baxalta
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Hemophilia Drugs Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Baxalta Hemophilia Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Bayer
  6.2.2 Hemophilia Drugs Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Bayer Hemophilia Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 CSL Behring
  6.3.2 Hemophilia Drugs Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 CSL Behring Hemophilia Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Novo Nordisk
  6.4.2 Hemophilia Drugs Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Novo Nordisk Hemophilia Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Pfizer
  6.5.2 Hemophilia Drugs Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Pfizer Hemophilia Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Roche
  6.6.2 Hemophilia Drugs Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Roche Hemophilia Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Alnylam Pharmaceuticals
  6.7.2 Hemophilia Drugs Product Category, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Alnylam Pharmaceuticals Hemophilia Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Amarna Therapeutics
  6.8.2 Hemophilia Drugs Product Category, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Amarna Therapeutics Hemophilia Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 Asklepios BioPharmaceutical
  6.9.2 Hemophilia Drugs Product Category, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Asklepios BioPharmaceutical Hemophilia Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 Biogen
  6.10.2 Hemophilia Drugs Product Category, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Biogen Hemophilia Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview
6.11 BioMarin
6.12 Catalyst Bioscience
6.13 Chiesi Farmaceutici
6.14 Dimension Therapeutics
6.15 Emergent BioSolutions
6.16 Grifols, Kedrion Biopharma
6.17 Octapharma
6.18 rEVO Biologics
6.19 OPKO Biologics
6.20 Sangamo Biosciences
6.21 Spark Therapeutics
6.22 Swedish Orphan Biovitrum
6.23 UniQure Biopharma.

7 HEMOPHILIA DRUGS MANUFACTURING COST ANALYSIS

7.1 Hemophilia Drugs Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Hemophilia Drugs

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Hemophilia Drugs Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Hemophilia Drugs Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES HEMOPHILIA DRUGS MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)

11.1 United States Hemophilia Drugs Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Hemophilia Drugs Sales Volume Forecast by Type (2017-2022)
11.3 United States Hemophilia Drugs Sales Volume Forecast by Application (2017-2022)
11.4 United States Hemophilia Drugs Sales Volume Forecast by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Hemophilia Drugs
Figure United States Hemophilia Drugs Market Size (K MT) by Type (2012-2022)
Figure United States Hemophilia Drugs Sales Volume Market Share by Type (Product Category) in 2016
Figure Hemophilia A Product Picture
Figure Hemophilia B Product Picture
Figure Hemophilia C Product Picture
Figure United States Hemophilia Drugs Market Size (K MT) by Application (2012-2022)
Figure United States Sales Market Share of Hemophilia Drugs by Application in 2016
Figure Clinic Examples
Table Key Downstream Customer in Clinic
Figure Hospital Examples
Table Key Downstream Customer in Hospital
Figure United States Hemophilia Drugs Market Size (Million USD) by Region (2012-2022)
Figure The West Hemophilia Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Hemophilia Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Hemophilia Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Hemophilia Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Hemophilia Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Hemophilia Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Hemophilia Drugs Sales (K MT) and Growth Rate (2012-2022)
Figure United States Hemophilia Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Hemophilia Drugs Market Major Players Product Sales Volume (K MT) (2012-2017)
Table United States Hemophilia Drugs Sales (K MT) of Key Players/Suppliers (2012-2017)
Table United States Hemophilia Drugs Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Hemophilia Drugs Sales Share by Players/Suppliers
Figure 2017 United States Hemophilia Drugs Sales Share by Players/Suppliers
Figure United States Hemophilia Drugs Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Hemophilia Drugs Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Hemophilia Drugs Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Hemophilia Drugs Revenue Share by Players/Suppliers
Figure 2017 United States Hemophilia Drugs Revenue Share by Players/Suppliers
Table United States Market Hemophilia Drugs Average Price (USD/MT) of Key Players/Suppliers (2012-2017)
Figure United States Market Hemophilia Drugs Average Price (USD/MT) of Key Players/Suppliers in 2016
Figure United States Hemophilia Drugs Market Share of Top 3 Players/Suppliers
Figure United States Hemophilia Drugs Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Hemophilia Drugs Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Hemophilia Drugs Product Category
Table United States Hemophilia Drugs Sales (K MT) by Region (2012-2017)
Table United States Hemophilia Drugs Sales Share by Region (2012-2017)
Figure United States Hemophilia Drugs Sales Share by Region (2012-2017)
Figure United States Hemophilia Drugs Sales Market Share by Region in 2016
Table United States Hemophilia Drugs Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Hemophilia Drugs Revenue Share by Region (2012-2017)
Figure United States Hemophilia Drugs Revenue Market Share by Region (2012-2017)
Figure United States Hemophilia Drugs Revenue Market Share by Region in 2016
Table United States Hemophilia Drugs Price (USD/MT) by Region (2012-2017)
Table United States Hemophilia Drugs Sales (K MT) by Type (2012-2017)
Table United States Hemophilia Drugs Sales Share by Type (2012-2017)
Figure United States Hemophilia Drugs Sales Share by Type (2012-2017)
Figure United States Hemophilia Drugs Sales Market Share by Type in 2016
Table United States Hemophilia Drugs Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Hemophilia Drugs Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Hemophilia Drugs by Type (2012-2017)
Figure Revenue Market Share of Hemophilia Drugs by Type in 2016
Table United States Hemophilia Drugs Price (USD/MT) by Types (2012-2017)
Figure United States Hemophilia Drugs Sales Growth Rate by Type (2012-2017)
Table United States Hemophilia Drugs Sales (K MT) by Application (2012-2017)
Table United States Hemophilia Drugs Sales Market Share by Application (2012-2017)
Figure United States Hemophilia Drugs Sales Market Share by Application (2012-2017)
Figure United States Hemophilia Drugs Sales Market Share by Application in 2016
Table United States Hemophilia Drugs Sales Growth Rate by Application (2012-2017)
Figure United States Hemophilia Drugs Sales Growth Rate by Application (2012-2017)
Table Baxalta Basic Information List
Table Baxalta Hemophilia Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Baxalta Hemophilia Drugs Sales Growth Rate (2012-2017)
Figure Baxalta Hemophilia Drugs Sales Market Share in United States (2012-2017)
Figure Baxalta Hemophilia Drugs Revenue Market Share in United States (2012-2017)
Table Bayer Basic Information List
Table Bayer Hemophilia Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Bayer Hemophilia Drugs Sales Growth Rate (2012-2017)
Figure Bayer Hemophilia Drugs Sales Market Share in United States (2012-2017)
Figure Bayer Hemophilia Drugs Revenue Market Share in United States (2012-2017)
Table CSL Behring Basic Information List
Table CSL Behring Hemophilia Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure CSL Behring Hemophilia Drugs Sales Growth Rate (2012-2017)
Figure CSL Behring Hemophilia Drugs Sales Market Share in United States (2012-2017)
Figure CSL Behring Hemophilia Drugs Revenue Market Share in United States (2012-2017)
Table Novo Nordisk Basic Information List
Table Novo Nordisk Hemophilia Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Novo Nordisk Hemophilia Drugs Sales Growth Rate (2012-2017)
Figure Novo Nordisk Hemophilia Drugs Sales Market Share in United States (2012-2017)
Figure Novo Nordisk Hemophilia Drugs Revenue Market Share in United States (2012-2017)
Table Pfizer Basic Information List
Table Pfizer Hemophilia Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Pfizer Hemophilia Drugs Sales Growth Rate (2012-2017)
Figure Pfizer Hemophilia Drugs Sales Market Share in United States (2012-2017)
Figure Pfizer Hemophilia Drugs Revenue Market Share in United States (2012-2017)
Table Roche Basic Information List
Table Roche Hemophilia Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Roche Hemophilia Drugs Sales Growth Rate (2012-2017)
Figure Roche Hemophilia Drugs Sales Market Share in United States (2012-2017)
Figure Roche Hemophilia Drugs Revenue Market Share in United States (2012-2017)
Table Alnylam Pharmaceuticals Basic Information List
Table Alnylam Pharmaceuticals Hemophilia Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Alnylam Pharmaceuticals Hemophilia Drugs Sales Growth Rate (2012-2017)
Figure Alnylam Pharmaceuticals Hemophilia Drugs Sales Market Share in United States (2012-2017)
Figure Alnylam Pharmaceuticals Hemophilia Drugs Revenue Market Share in United States (2012-2017)
Table Amarna Therapeutics Basic Information List
Table Amarna Therapeutics Hemophilia Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Amarna Therapeutics Hemophilia Drugs Sales Growth Rate (2012-2017)
Figure Amarna Therapeutics Hemophilia Drugs Sales Market Share in United States (2012-2017)
Figure Amarna Therapeutics Hemophilia Drugs Revenue Market Share in United States (2012-2017)
Table Asklepios BioPharmaceutical Basic Information List
Table Asklepios BioPharmaceutical Hemophilia Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Asklepios BioPharmaceutical Hemophilia Drugs Sales Growth Rate (2012-2017)
Figure Asklepios BioPharmaceutical Hemophilia Drugs Sales Market Share in United States (2012-2017)
Figure Asklepios BioPharmaceutical Hemophilia Drugs Revenue Market Share in United States (2012-2017)
Table Biogen Basic Information List
Table Biogen Hemophilia Drugs Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Biogen Hemophilia Drugs Sales Growth Rate (2012-2017)
Figure Biogen Hemophilia Drugs Sales Market Share in United States (2012-2017)
Figure Biogen Hemophilia Drugs Revenue Market Share in United States (2012-2017)
Table BioMarin Basic Information List
Table Catalyst Bioscience Basic Information List
Table Chiesi Farmaceutici Basic Information List
Table Dimension Therapeutics Basic Information List
Table Emergent BioSolutions Basic Information List
Table Grifols, Kedrion Biopharma Basic Information List
Table Octapharma Basic Information List
Table rEVO Biologics Basic Information List
Table OPKO Biologics Basic Information List
Table Sangamo Biosciences Basic Information List
Table Spark Therapeutics Basic Information List
Table Swedish Orphan Biovitrum Basic Information List
Table UniQure Biopharma. Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Hemophilia Drugs
Figure Manufacturing Process Analysis of Hemophilia Drugs
Figure Hemophilia Drugs Industrial Chain Analysis
Table Raw Materials Sources of Hemophilia Drugs Major Players/Suppliers in 2016
Table Major Buyers of Hemophilia Drugs
Table Distributors/Traders List
Figure United States Hemophilia Drugs Sales Volume (K MT) and Growth Rate Forecast (2017-2022)
Figure United States Hemophilia Drugs Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Hemophilia Drugs Price (USD/MT) Trend Forecast (2017-2022)
Table United States Hemophilia Drugs Sales Volume (K MT) Forecast by Type (2017-2022)
Figure United States Hemophilia Drugs Sales Volume (K MT) Forecast by Type (2017-2022)
Figure United States Hemophilia Drugs Sales Volume (K MT) Forecast by Type in 2022
Table United States Hemophilia Drugs Sales Volume (K MT) Forecast by Application (2017-2022)
Figure United States Hemophilia Drugs Sales Volume (K MT) Forecast by Application (2017-2022)
Figure United States Hemophilia Drugs Sales Volume (K MT) Forecast by Application in 2022
Table United States Hemophilia Drugs Sales Volume (K MT) Forecast by Region (2017-2022)
Table United States Hemophilia Drugs Sales Volume Share Forecast by Region (2017-2022)
Figure United States Hemophilia Drugs Sales Volume Share Forecast by Region (2017-2022)
Figure United States Hemophilia Drugs Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources